Parkside Financial Bank & Trust boosted its holdings in shares of Pfizer Inc. (NYSE: PFE – Get Rating) by 4.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,445 shares of the biopharmaceutical company stock after buying an additional 1,759 shares during the period. Pfizer makes up 0.6% of Parkside Financial Bank & Trust’s holdings, making its stock its 28th largest position. Parkside Financial Bank & Trust’s holdings in Pfizer were worth $ 2,270,000 as of its most recent SEC filing.
A number of other large investors have also made changes to their positions in the stock. OLD Mission Capital LLC acquired a new position in shares of Pfizer in the third quarter valued at about $ 291,000. Morgan Stanley grew its holdings in Pfizer by 3.4% during the second quarter. Morgan Stanley now owns 47,894,080 shares of the biopharmaceutical company stock worth $ 1,875,532,000 after acquiring an additional 1,582,052 shares during the period. Center for Financial Planning Inc. grew its holdings in Pfizer by 1.9% during the third quarter. Center for Financial Planning Inc. now owns 17,073 shares of the biopharmaceutical company stock worth $ 734,000 after acquiring an additional 313 shares during the period. New World Advisors LLC acquired a new stake in Pfizer during the third quarter worth about $ 292,000. Finally, EagleClaw Capital Managment LLC grew its holdings in Pfizer by 2.1% during the third quarter. EagleClaw Capital Managment LLC now owns 29,959 shares of the biopharmaceutical company stock worth $ 1,287,000 after acquiring an additional 625 shares during the period. 66.50% of the stock is currently owned by institutional investors.
In other news, SVP Jennifer B. Damico sold 4,218 shares of the business’s stock in a transaction that occurred on Tuesday, June 7th. The stock was sold at an average price of $ 53.96, for a total transaction of $ 227,603.28. Following the sale, the senior vice president now owns 10,846 shares of the company stock, valued at approximately $ 585,250.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of the company stock in a transaction that occurred on Thursday, May 12th. The shares were sold at an average price of $ 50.00, for a total value of $ 1,645,400.00. Following the completion of the sale, the executive vice president now directly owns 38,146 shares in the company, valued at approximately $ 1,907,300. The disclosure for this sale can be found here. Insiders have sold a total of 41,126 shares of company stock worth $ 2,075,003 in the last quarter. 0.05% of the stock is currently owned by insiders.
A number of equities analysts have issued reports on PFE shares. Wells Fargo & Company lowered their price target on Pfizer from $ 60.00 to $ 55.00 in a research report on Wednesday, May 4th. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, April 19th. JPMorgan Chase & Co. set a $ 57.00 price target on Pfizer in a research report on Tuesday, May 3rd. SVB Leerink started coverage on Pfizer in a research report on Monday, May 23rd. They set a “market perform” rating and a $ 55.00 price target on the stock. Finally, Berenberg Bank set a $ 50.00 target price on Pfizer in a research report on Friday, May 27th. Nine analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $ 57.26.
Shares of NYSE PFE opened at $ 46.53 on Friday. The company has a market capitalization of $ 261.07 billion, a price-to-earnings ratio of 10.67, a price-to-earnings-growth ratio of 0.59 and a beta of 0.76. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.39 and a quick ratio of 1.13. The business has a 50-day moving average of $ 50.90 and a two-hundred day moving average of $ 52.34. Pfizer Inc. has a 1 year low of $ 38.70 and a 1 year high of $ 61.71.
Pfizer (NYSE: PFE – Get Rating) last announced its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $ 1.62 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $ 1.66 by ($ 0.04). Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The business had revenue of $ 25.66 billion for the quarter, compared to analysts’ expectations of $ 24.73 billion. During the same period last year, the firm earned $ 0.93 earnings per share. The firm’s quarterly revenue was up 76.8% on a year-over-year basis. As a group, equities research analysts expect that Pfizer Inc. will post 6.62 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Friday, June 10th. Shareholders of record on Friday, May 13th were given a dividend of $ 0.40 per share. This represents a $ 1.60 annualized dividend and a yield of 3.44%. The ex-dividend date of this dividend was Thursday, May 12th. Pfizer’s payout ratio is 36.70%.
Pfizer Company Profile: (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Read More:
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE: PFE – Get Rating).
Receive News & Ratings for Pfizer Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.
.